Earnings ·
Hemab Therapeutics reports Q3 net loss of $27.3M, initiates pivotal Phase 3 trial for sutacimig
COAGHemab Therapeutics Holdings, Inc.
Hemab Therapeutics reported a third-quarter net loss of $27.3 million, or $0.58 per share, compared to a $17.1 million loss in the prior-year period. Cash and equivalents stood at $430.2 million as of September 30, 2026, providing runway into 2029. The company initiated SOLARA, a pivotal Phase 3 trial for sutacimig in Glanzmann thrombasthenia, dosed the first participant in its Phase 1 trial for HMB-003 in heavy menstrual bleeding, and appointed Keli Walbert to its Board of Directors. Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders.